Slingshot members are tracking this event:
Bristol-Myers Squibb's (BMY) Phase 3 CheckMate of Opdivo Plus Low-Dose Yervoy in Lung Cancer Patients with High Tumor Mutational Burden Data Presented at AACR
Do you think this event is important to the companies below? How will it affect their stock price?
Additional data from CheckMate -227 presented at AACR 2018 include subgroup analyses by tumor PD-L1 expression in patients with TMB ≥10 mut/Mb. In these analyses, PFS was significantly improved with the combination versus chemotherapy in patients with PD-L1 ≥1% (HR 0.62; 95% CI: 0.44 to 0.88) and PD-L1 <1% (HR 0.48; 95% CI: 0.27 to 0.85). Increased benefit with Opdivo plus low-dose Yervoyversus chemotherapy was also observed in patients with squamous histology (HR 0.63; 95% CI: 0.39 to 1.04) and non-squamous histology (HR 0.55; 95% CI: 0.38 to 0.80).In the study, PFS also was evaluated with Opdivo versus chemotherapy among patients with TMB ≥13 mut/Mb and ≥1% PD-L1 expression as a secondary endpoint. An improvement in PFS with Opdivo monotherapy was not observed (HR 0.95; 97.5% CI: 0.61 to 1.48; p=0.7776).
Slingshot Insights Explained
Apr 16, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Checkmate, Phase 3 Study, Opdivo, Yervoy, Lung Cancer